Asset Details
Do you wish to reserve the book?
α‐Synuclein seed amplification assay in Lewy body dementia versus Alzheimer's disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
α‐Synuclein seed amplification assay in Lewy body dementia versus Alzheimer's disease
Do you wish to request the book?
α‐Synuclein seed amplification assay in Lewy body dementia versus Alzheimer's disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
α‐Synuclein seed amplification assay in Lewy body dementia versus Alzheimer's disease
2025
Overview
INTRODUCTION Differentiating dementia with Lewy bodies (DLB) from Alzheimer's disease (AD) is challenging. Seed amplification assay (SAA) is sensitive for the detection of misfolded α‐synuclein. METHODS Patients with DLB (N = 31) and AD (N = 25) were recruited and evaluated. Misfolded α‐synuclein was assessed in cerebrospinal fluid (CSF), skin, urine, and olfactory mucosa using SAA. RESULTS The accuracy of α‐synuclein‐SAA for DLB was 87% (95% confidence interval [CI]: 77% to 98%) in CSF, 85% (95% CI: 75% to 98%) in skin, 58% (95% CI: 47% to 69%) in olfactory mucosa, and 59% (95% CI: 51% to 66%) in urine. The core symptoms – fluctuations, REM sleep behavior disorder, and parkinsonism – had accuracies for SAA positivity of ≥79%. Notably, 95% of SAA‐positive patients also had hyposmia. DISCUSSION These findings support the use of CSF and skin α‐synuclein‐SAAs as diagnostic tools for DLB, with strong associations between SAA and clinical phenotype. In particular, intact olfactory function is associated with a lower risk of SAA positivity. Highlights CSF and skin biopsies show high diagnostic accuracy for α‐synuclein, demonstrating good concordance. Strong correlations exist between core symptoms of DLB and pathological α‐synuclein. A very high sensitivity of hyposmia for pathological α‐synuclein is observed. A novel proof‐of‐concept is offered for the potential detection of pathological α‐synuclein in urine, marking the first such comparative analysis between patients with DLB and AD.
